2024
Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease
Li H, Huntington S, Gross C, Wang S. Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease. PLOS ONE 2024, 19: e0300789. PMID: 38625861, PMCID: PMC11020359, DOI: 10.1371/journal.pone.0300789.Peer-Reviewed Original ResearchConceptsAutoimmune diseasesImmunotherapy cycleFirst-lineNon-small cell lung cancerAdvanced cancerFirst-line immunotherapyOverall treatment toleranceCell lung cancerRenal cell carcinomaRetrospective cohort studyAssociated with lower oddsAdvanced melanomaCell carcinomaTreatment toleranceAbsolute contraindicationImmunotherapyConsensus guidelinesImprove cancer survivalLung cancerCohort studyClinical variablesCancer patientsAcademic centersPatientsIncidence rate
2022
Perceptions of Transfusion Access and Hospice Among Patients with Advanced Hematologic Malignancies (RP525)
Odejide O, Huntington S, Hurley S, Kaufman R, Shi E, Johnson K, Tulsky J, Abel G. Perceptions of Transfusion Access and Hospice Among Patients with Advanced Hematologic Malignancies (RP525). Journal Of Pain And Symptom Management 2022, 63: 1111-1112. DOI: 10.1016/j.jpainsymman.2022.04.091.Peer-Reviewed Original ResearchHospice servicesBlood cancersHospice useHematologic malignanciesUtility scoresAdvanced hematologic malignanciesBlood cancer patientsCaregiver focus groupsAdult patientsBlood transfusionMedian ageCancer CenterCancer patientsAcute leukemiaHospice modelValue patientsMedical appointmentsCancer placesPatientsRespite careWeb-based surveyTransfusionCancerCognitive debriefingMalignancy
2021
Perceptions of Prognosis Among Patients with Advanced Hematologic Malignancies
Odejide O, Huntington S, Kuczmarski T, Shi E, Tulsky J, Abel G. Perceptions of Prognosis Among Patients with Advanced Hematologic Malignancies. Blood 2021, 138: 4026. DOI: 10.1182/blood-2021-153361.Peer-Reviewed Original ResearchHealthcare teamPrognostic discussionsHematologic oncologistsBlood cancersUnivariable analysisLife expectancyHematologic malignanciesAdvanced hematologic malignanciesHalf of patientsCohort of patientsLarge cancer centerPerceptions of prognosisBlood cancer patientsAccurate prognostic understandingEnd of lifeAdult patientsCommon diagnosisMedian timeOutpatient visitsCancer CenterCancer patientsPrognostic understandingAcute leukemiaPatients' perceptionsOwn life expectancyPerceptions of Hospice and Transfusion Access Among Patients with Advanced Blood Cancers: Results from a Best-Worst Scaling Survey
Odejide O, Huntington S, Shi E, Johnson K, Tulsky J, Abel G. Perceptions of Hospice and Transfusion Access Among Patients with Advanced Blood Cancers: Results from a Best-Worst Scaling Survey. Blood 2021, 138: 3020. DOI: 10.1182/blood-2021-153304.Peer-Reviewed Original ResearchBlood cancersCancer CenterHematologic malignanciesHospice servicesUtility scoresLarge cancer centerConfidence intervalsPerceptions of patientsBlood cancer patientsPerspectives of patientsDays of lifeYears of ageQuality of lifeCaregiver focus groupsEligible patientsHematologic oncologistsBlood transfusionMedian ageCommon diagnosisOutpatient visitsCancer patientsHospice useStudy inclusionAcute leukemiaPatients' perceptions
2020
Perspectives Regarding Hospice Services and Transfusion Access: Focus Groups With Blood Cancer Patients and Bereaved Caregivers
Henckel C, Revette A, Huntington SF, Tulsky JA, Abel GA, Odejide OO. Perspectives Regarding Hospice Services and Transfusion Access: Focus Groups With Blood Cancer Patients and Bereaved Caregivers. Journal Of Pain And Symptom Management 2020, 59: 1195-1203.e4. PMID: 31926969, PMCID: PMC7239741, DOI: 10.1016/j.jpainsymman.2019.12.373.Peer-Reviewed Original ResearchConceptsQuality of lifeBlood cancer patientsHospice servicesBereaved caregiversBlood cancersCancer patientsInnovative care delivery modelsPerspectives of patientsCare delivery modelsFocus groupsHematologic oncologistsHospice useLife careTransfusionPatientsHospice settingsQOL domainsPotential associationOverall positive experienceCancerCaregiversLife expectancyLower ratesResearch assistantsDelivery model
2016
Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population‐Based Study
Wang R, Zeidan AM, Yu JB, Soulos PR, Davidoff AJ, Gore SD, Huntington SF, Gross CP, Ma X. Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population‐Based Study. The Prostate 2016, 77: 437-445. PMID: 27868212, PMCID: PMC5785924, DOI: 10.1002/pros.23281.Peer-Reviewed Original ResearchConceptsMDS/acute myeloid leukemiaAcute myeloid leukemiaProstate cancer patientsElderly prostate cancer patientsImpact of radiotherapyCancer patientsMyelodysplastic syndromeNational Cancer Institute's SurveillanceSubsequent myelodysplastic syndromeEnd Results-MedicareRetrospective cohort studyRole of radiotherapyInformed treatment decisionsUnderwent radiotherapyIMRT groupCohort studyPatient characteristicsMedian timeMyeloid leukemiaProstate cancerTreatment decisionsPatientsRadiotherapyMyeloid malignanciesSurgery